FDA Approves First RNAi Silencer for Rare Type of Cardiomyopathy

The approval of Alnylam’s Amvuttra sets up a three-way race with Pfizer and BridgeBio, which both market transthyretin stabilizers for transthyretin amyloid cardiomyopathy.